RehHomo sapiens (Human)Cancer cell line
Also known as: REH
Quick Overview
Human B-cell acute lymphoblastic leukemia cell line with TEL-AML1 fusion.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1650 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 15 |
|---|---|
| Age Category | Pediatric |
| Sex | Female |
| Race | north_african |
| Subtype Features | ETV6-RUNX1 |
Disease Information
| Disease | Childhood B acute lymphoblastic leukemia |
|---|---|
| Lineage | Lymphoid |
| Subtype | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 |
| OncoTree Code | BLLETV6RUNX1 |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000960_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | ETV6 | ETV6-RUNX1, TEL-AML1 | - | ETV6 exon 5/RUNX1 exon 4 and RUNX1 exon 3/ETV6 exon 6 fusions | from parent cell line Reh |
| MutationSimple | NR3C1 | p.Gln527Ter (c.1579C>T) (p.Gln528Ter, c.1582C>T) | Homozygous | - | PubMed=35124168 |
| MutationSimple | PTEN | p.Arg173Cys (c.517C>T) | Homozygous | - | from parent cell line Reh |
| MutationSimple | TP53 | p.Arg181Cys (c.541C>T) | Heterozygous | - | PubMed=21173094, PubMed=1373872 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.
Lehtio J., Vesterlund M., Jafari R.
Nat. Commun. 13:1691.1-1691.19(2022).
Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
Minegishi M., Iwamoto S., Sugita K., Inukai T.
J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Further characterization of a non-T, non-B acute lymphoblastic leukaemia cell line (Reh). Reactivity with human sera cytotoxic for leukaemia cells.
Bertoglio J., Guibout C., Dore J.-F., Rosenfeld C.
Cancer Immunol. Immunother. 4:193-196(1978).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
An effect human leukaemic cell line: Reh.";
Dore J.-F., Liabeuf A., Durandy A., Desgranges C., de The G.B.
Eur. J. Cancer 13:377-379(1977).
Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line.
Pico J.-L., Greaves M.F.
Nature 267:841-843(1977).
Metabolism of proline in a human leukemic lymphoblastoid cell line.";
Lorans G., Rosenfeld C., Petitou M., Phan-Dinh-Tuy F., Mathe G.
Cancer Res. 38:3950-3953(1978).
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Nakano A., Harada T., Morikawa S., Kato Y.
Acta Pathol. Jpn. 40:107-115(1990).
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1. carboxylic esterase.
Drexler H.G., Gaedicke G., Minowada J.
Leuk. Res. 9:209-229(1985).
Isoenzyme studies in human leukemia-lymphoma cell lines -- III. Beta-hexosaminidase (E.C. 3.2.1.30).
Drexler H.G., Gaedicke G., Minowada J.
Leuk. Res. 9:549-559(1985).
In vitro study of the comparative behaviour of a human acute lymphoblastic leukemia cell line and a reference normal cell line towards the effects of a mitogenic lectin.
Bourrillon R.
Cancer Biochem. Biophys. 8:143-152(1985).
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Drexler H.G., Gaedicke G., Minowada J.
Leuk. Res. 9:537-548(1985).
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Findley H.W. Jr.
Leukemia 9:1159-1161(1995).
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Zhou M.-X., Yeager A.M., Smith S.D., Findley H.W. Jr.
Blood 85:1608-1614(1995).
TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines.
Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D., Smith S.D.
Blood 88:785-794(1996).
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Nakamura H., Amakawa R., Ohno H.
Leukemia 10:1592-1603(1996).
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Janssen J.W.G., Drexler H.G.
Leukemia 11:441-447(1997).
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Findley H.W. Jr., Gu L.-B., Yeager A.M., Zhou M.-X.
Blood 89:2986-2993(1997).
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Hirai H.
Jpn. J. Cancer Res. 89:33-39(1998).
Establishment and characterization of human B cell precursor-leukemia cell lines.
Matsuo Y., Drexler H.G.
Leuk. Res. 22:567-579(1998).
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Zhou M.-X., Gu L.-B., Yeager A.M., Findley H.W. Jr.
Leukemia 12:1756-1763(1998).
EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1.
Fu X.-Y., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.
Oncogene 18:4920-4929(1999).
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 24:255-262(2000).
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 25:275-278(2001).
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Tsuchida M., Sugita K., Ida K., Hayashi Y.
Blood 103:1085-1088(2004).
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Fioretos T.
Leukemia 19:1042-1050(2005).
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
Leukemia 20:471-476(2006).
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Dexter T.J., Ashworth A., Kearney L.
Genes Chromosomes Cancer 45:554-564(2006).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.
Tada M., Moriuchi T., Sugita K.
Am. J. Hematol. 85:535-537(2010).
Survey of activated FLT3 signaling in leukemia.";
Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.
PLoS ONE 6:E19169-E19169(2011).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Single-cell mutational profiling and clonal phylogeny in cancer.";
Greaves M.F.
Genome Res. 23:2115-2125(2013).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
Yarranton G.T., Woronicz J., Scott A.M., Lackmann M., Boyd A.W.
Leukemia 31:1779-1787(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression.
Sugita K.
Cell Death Dis. 8:e2857.1-e2857.11(2017).
Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
Sugita K., Hosoi H.
Int. J. Hematol. 108:312-318(2018).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).